NR3C1 and plasma cell myeloma: The NR3C1-targeting miR-130b was found to exhibit higher expression in a glucocorticoid-insensitive multiple myeloma cell line, and its introduction into a glucocorticoid-sensitive line impaired the cellular response to glucocorticoid treatment, including the induction of apoptosis [37].